Minimalizing bleeding and tearing at vaginal birth: One practitioner's experience.
Minimalizing bleeding and tearing at vaginal birth: One practitioner's experience. Women Birth. 2017 Aug 10;: Authors: Cohain JS PMID: 28803885 [PubMed - as supplied by publisher]
We examined the proportions of use of TRA, the influence on in-hospital outcomes, and adjusted long-term effects. Results The rate of TRA rose from 15.9% in period 1 to 69.1% in period 2, including in specific situations such as acute coronary syndrome, chronic total occlusion, bifurcation, calcified lesions, and unprotected left main PCI. In-hospital rates of bleeding were lower for TRA versus transfemoral artery (1.8 vs. 5.1%, overall, P
Conclusion Compared with heparin plus GPI or bivalirudin plus GPI, bivalirudin monotherapy provides similar protection from ischemic events with less major bleeding at 30 days among patients with NSTE-ACS and positive biomarkers.
SummaryTAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid tumors. This open-label, dose-escalation phase I study of TAS-115 consisted of three parts: part 1 (TAS-115 was administered orally once daily [SID]); part 2 and an expansion part (SID in a 5 days on/2 days off [5-on/2-off] schedule for 21 days per cycle). In part 1 (200–800 mg SID administered to 21 patients), systemic exposure after...
For some patients, combining aspirin and direct oral anticoagulant (DOAC) therapy may increase the rates of bleeding without protecting them from adverse thrombotic outcomes, a new study has found.Medscape Medical News
This study included 1249 consecutive patients undergoing either transcatheter aortic valve implantation (TAVI), Mitraclip, left atrial appendage occlusion (LAAO) or paravalvular leak closure (PVLC). Patients were divided into two cohorts based on the degree of probe manipulation required to guide the procedure and the risk of developing a TEE-related complication: low-risk (TAVI, n = 1037) and high-risk (Mitraclip, LAAO and PVLC, n = 212). Patients were further analyzed according to the occurrence of major and minor TEE-related complications.ResultsThe overall incidence of TEE-related complications was ...
Elderly patients may have increased platelet reactivity and adverse events after percutaneous coronary intervention (PCI). Whether age is an independent predictor of worse outcomes after accounting for platelet reactivity is unknown. We sought to determine the relationship between age and platelet reactivity on 2-year outcomes after PCI with drug-eluting stents (DES). ADAPT-DES was a prospective observational registry comprising 8582 DES-treated patients. Patients were categorized with an age cut-off of 75 years.
The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation undergoing percutaneous coronary intervention, with noninferiority in composite thromboembolic events. In this prespecified analysis, risks of first major or clinically relevant nonmajor bleeding event and composite end point of death, thromboembolic events, or unplanned revascularization were compared between dabigatran dual therapy and warfarin triple therapy in ...
Endoscopy DOI: 10.1055/a-1065-1678 © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Full text
ConclusionsIntraoperative events and 1-year postoperative complications were high for both Lichtenstein –Lichtenstein and Laparoscopy–Laparoscopy, and the results therefore support guidelines that recommend another approach at reoperation.
DiscussionThere have been no randomised controlled trials that have compared the safety and efficacy of FFP versus PCC in cardiac surgery patients who are bleeding. This pilot study will assess if individual components of a large trial are deliverable to assess the safety and efficacy of the two blood products in the future.Trial registrationEudraCT, 2018-003041-41; ClinicalTrials.gov,NCT03715348. Registered on 29 July 2018.